Immunic Inc Cash Flow Conversion Efficiency
Immunic Inc cash flow conversion efficiency. Based on the latest financial reports, Immunic Inc (IMUX) has a cash flow conversion efficiency ratio of 2.889x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.28 Million) by net assets ($-6.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Immunic Inc (2011–2025)
Cash flow conversion efficiency of Immunic Inc from 2011 to 2025. This chart illustrates how Immunic Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View IMUX stock price for real-time trading data and today's change.
Immunic Inc Cash Flow Conversion Ratio Explained
Immunic Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Immunic Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunic Inc ranked by their cash flow conversion efficiency. Also see market value of Immunic Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Marks and Spencer Group PLC
LSE:MKS
|
0.289x |
|
Synchronoss Technologies Inc
NASDAQ:SNCR
|
0.711x |
|
Falco Resources Ltd
V:FPC
|
-0.005x |
|
Merkur PrivatBank KgaA
XETRA:MBK
|
N/A |
|
FSA Group Ltd
AU:FSA
|
0.105x |
|
Syrah Resources Ltd
AU:SYR
|
-0.089x |
|
Southern Acids (M) Bhd
KLSE:5134
|
0.068x |
|
Alan Allman Associates SA
PA:AAA
|
0.339x |
Annual Cash Flow Conversion Efficiency for Immunic Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Immunic Inc from 2011 to 2025. Review how financially flexible is Immunic Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-6.67 Million | $-85.81 Million | 12.859x | +379.56% |
| 2024-12-31 | $18.43 Million | $-84.77 Million | -4.600x | -87.88% |
| 2023-12-31 | $28.93 Million | $-70.83 Million | -2.448x | -327.23% |
| 2022-12-31 | $113.68 Million | $-65.14 Million | -0.573x | +12.49% |
| 2021-12-31 | $127.11 Million | $-83.23 Million | -0.655x | -125.41% |
| 2020-12-31 | $158.78 Million | $-46.12 Million | -0.290x | +40.61% |
| 2019-12-31 | $58.36 Million | $-28.55 Million | -0.489x | +85.92% |
| 2018-12-31 | $12.43 Million | $-43.16 Million | -3.473x | -330.30% |
| 2017-12-31 | $50.04 Million | $-40.40 Million | -0.807x | -31.88% |
| 2016-12-31 | $58.45 Million | $-35.77 Million | -0.612x | -0.88% |
| 2015-12-31 | $82.33 Million | $-49.95 Million | -0.607x | -45.00% |
| 2014-12-31 | $97.56 Million | $-40.83 Million | -0.418x | +39.50% |
| 2013-12-31 | $41.42 Million | $-28.65 Million | -0.692x | -157.11% |
| 2012-12-31 | $-7.63 Million | $-9.24 Million | 1.211x | +748.41% |
| 2011-12-31 | $-54.85 Million | $-7.83 Million | 0.143x | -- |
About Immunic Inc
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative… Read more